TY - JOUR
T1 - Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A(2) mass in type 2 diabetes mellitus
T2 - Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity
AU - Constantinides, Alexander
AU - de Vries, Rindert
AU - van Leeuwen, Jeroen J. J.
AU - Gautier, Thomas
AU - van Pelt, L. Joost
AU - Tselepis, Alexandros D.
AU - Lagrost, Laurent
AU - Dullaart, Robin P. F.
PY - 2012/10
Y1 - 2012/10
N2 - Objective: Plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels predict incident cardiovascular disease, impacting Lp-PLA(2) as an emerging therapeutic target. We determined Lp-PLA(2) responses to statin and fibrate administration in type 2 diabetes mellitus, and assessed relationships of changes in Lp-PLA(2) with subclinical inflammation and lipoprotein characteristics.Methods: A placebo-controlled cross-over study (three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily) and their combination) was carried out in 14 male type 2 diabetic patients. Plasma Lp-PLA(2) mass was measured by turbidimetric immunoassay.Results: Plasma Lp-PLA(2) decreased (-21 +/- 4%) in response to simvastatin (pConclusions: In type 2 diabetes mellitus, plasma Lp-PLA(2) is likely to be lowered by statin treatment only. Enhanced subclinical inflammation and more severe dyslipidemia may predict diminished LpPLA(2) responses during lipid lowering treatment, which in turn appear to be quantitatively dissociated from decreases in apolipoprotein B lipoproteins. Conventional lipid lowering treatment may be insufficient for optimal LpPLA(2) lowering in diabetes mellitus. (C) 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
AB - Objective: Plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels predict incident cardiovascular disease, impacting Lp-PLA(2) as an emerging therapeutic target. We determined Lp-PLA(2) responses to statin and fibrate administration in type 2 diabetes mellitus, and assessed relationships of changes in Lp-PLA(2) with subclinical inflammation and lipoprotein characteristics.Methods: A placebo-controlled cross-over study (three 8-week treatment periods with simvastatin (40 mg daily), bezafibrate (400 mg daily) and their combination) was carried out in 14 male type 2 diabetic patients. Plasma Lp-PLA(2) mass was measured by turbidimetric immunoassay.Results: Plasma Lp-PLA(2) decreased (-21 +/- 4%) in response to simvastatin (pConclusions: In type 2 diabetes mellitus, plasma Lp-PLA(2) is likely to be lowered by statin treatment only. Enhanced subclinical inflammation and more severe dyslipidemia may predict diminished LpPLA(2) responses during lipid lowering treatment, which in turn appear to be quantitatively dissociated from decreases in apolipoprotein B lipoproteins. Conventional lipid lowering treatment may be insufficient for optimal LpPLA(2) lowering in diabetes mellitus. (C) 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
KW - Bezafibrate
KW - Lipoprotein-associated phospholipase A(2)
KW - High-sensitive C-reactive protein
KW - Low density lipoprotein electronegativity
KW - Simvastatin
KW - Type 2 diabetes mellitus
KW - CORONARY-HEART-DISEASE
KW - ACTIVATING-FACTOR ACETYLHYDROLASE
KW - COMBINATION THERAPY
KW - DOSE COMBINATION
KW - STATIN THERAPY
KW - LIPID THERAPY
KW - PAF-AH
KW - ATORVASTATIN
KW - DYSLIPIDEMIA
KW - EFFICACY
U2 - 10.1016/j.ejim.2012.05.008
DO - 10.1016/j.ejim.2012.05.008
M3 - Article
SN - 0953-6205
VL - 23
SP - 633
EP - 638
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
IS - 7
ER -